Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

ee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that the End of Phase II meeting will be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel, NGX426 or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact: Media Contact:

Craig Johnson David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x118 212-845-4271

cjohnson@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact: Investor Contact:

Rhonda Chiger John Baldissera

Rx Communications BPC Financial Marketing

917-322-2569 800-368-1217

rchiger@rxir.com

(Tables Follow)

TorreyPines Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

December
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 30, 2014 ... in Private Equity and Venture Capital Funding” report ... factors shaping the private equity and venture capital ... that these are expected to have significant impact ... the US and globally. Furthermore, the report identifies ...
(Date:7/29/2014)... The advanced optical methods and applications for imaging ... revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics . ... the BRAIN Initiative in the United States, and a ... for and provide examples of the impact that optics ...
(Date:7/29/2014)... , July 29, 2014 Human Longevity, Inc. ... company focused on extending the healthy, high performance human ... Och , Ph.D., an expert in machine learning and ... comes to HLI from Google where he was Distinguished ... will report directly to HLI Co-Founder and CEO, ...
(Date:7/29/2014)... 2014) Tough, ultralight foam of atom-thick sheets can ... chemical process invented at Rice University. , In ... nanoscale building, with floors and walls that reinforce each ... materials: floors and walls of graphene oxide that self-assemble ... , The researchers say the foam could find use ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2
... Vical Incorporated,(Nasdaq: VICL ) presentation at the ... at 1 p.m. Eastern Daylight Time, will be ... page at http://www.vical.com ., About Vical, ... on its,patented DNA delivery technologies for the prevention ...
... - Oncentra(R) RT Viewer* Officially to Launch ... ASTRO 2008, Boston, USA, September,21-24, Nucletron, a ... release of Oncentra RT Viewer. This unique innovation,in ... review,radiotherapy plans that are generated with a wide ...
... significant partial onset seizure reduction, proven ... - Keppra XR(TM) is ... press release, regulated information:,UCB announced today that the U.S. Food ... for use as,an add-on to other antiepileptic treatments for people ...
Cached Biology Technology:Vical to Present at UBS Global Life Sciences Conference 2Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy 2Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... The analysis of the roughly 3,000 pieces is still ... that the results will be of major significance. "Amazingly ... insect species in Fushun amber that we found in ... , The Baltic amber comes from the Baltic ... Sites rich in finds are, e.g., the coastal regions ...
(Date:7/30/2014)... unveiled the first high-resolution map of the carbon ... of Per. The new and improved methodology used ... for future market-based carbon economies. The new ... diversity and it provides the critical input to ... land use, and enforcement purposes. The technique includes ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... Theres more to biofuels than the food vs. fuel debate ... And so Steven Fales, a professor of agronomy ... Iowa States Bioeconomy Institute, organized and moderated a three-hour symposium ... American Association for the Advancement of Science in Boston. ...
... theory into practice to manage complex and closely linked ... challenge, but one NOAA researcher Anne Guerry says can ... value of our ocean resources. Guerry will ... people obtain from ecosystems, in managing marine resources in ...
... This release is available in French . , ... the University of Toronto to rev up the production of stem ... cells and embryonic stem cells. The end products are blood and ... they form beating tissue. To do this, he has ...
Cached Biology News:Iowa Staters talk biofuels, healthy oils and 'pharma crops' at AAAS meeting 2Can Dungeness crab and eelgrass help improve management of our marine resources? 2From stem cells to organs: The bioengineering challenge 2
Proline-serine-threonine phosphatase-interacting protein 2...
E2F2 protein...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: